Vicore Pharma’s holding I-Tech enters long-term commercial agreement with global marine paint company


Vicore Pharma Holding’s (publ) (ticker: VICO) associated company, I-Tech AB today announced the entering of a long-term commercial agreement with Chugoko Marine Paint (CMP). The agreement includes binding significant orders for Selektope®, I-Tech’s revolutionary and proprietary antifouling technology. The agreement follows in response to increasing demand for CMP’s Selektope®-containing antifouling products. 

Read the official pressrelease ;  

About Vicore Pharma Holding
Vicore Pharma AB develops drugs that act through the AT2 receptor. The company’s drug candidate C21 aims to improve the treatment of idiopathic pulmonary fibrosis, a rare disease for which C21 has been granted orphan drug designation both in the EU and USA. In addition, C21 is explored pre-clinically for a number of diseases where the AT2 receptor plays an important role. I-Tech AB is an associated company to Vicore Pharma Holding. The company has developed and commercialized Selektope®, an effective chemical agent used as an antifouling ingredient in antifouling paints. The companies are based in Astra Zeneca’s Bioventurehub in Mölndal. The company’s share (VICO) is listed for trading on Nasdaq First North in Stockholm with Erik Penser Bank as Certified Adviser. For more information, please refer to 

About I-Tech
I-Tech is a Gothenburg based bio-tech company with global reach, holding all IP and regulatory rights to the antifouling agent Selektope® (generic name, medetomidine). The company is privately held and is supported by Swedish Energy Association, the European Innovation Initiative Eco-Innovation and FP7 SeaFront. The company is a member of the Astra Zeneca BioVentureHub.